| European Case Law Identifier: | ECLI:EP:BA:2011:T062008.20110504 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 04 May 2011 | ||||||||
| Case number: | T 0620/08 | ||||||||
| Application number: | 00930450.2 | ||||||||
| IPC class: | C07D 405/12 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ||||||||
| Applicant name: | ENCYSIVE PHARMACEUTICALS, INC. | ||||||||
| Opponent name: | Vertex Pharmaceuticals Incorporated | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of documents late-filed during opposition proceedings: (yes) partly Late-filed ground for opposition - considered Main, first and second auxiliary request: novelty (no) special - meaning of terms used in patent specification considered Adjournment of oral proceedings (no) - no new issues Fourth auxiliary request: novelty (yes); inventive step (yes) - oxo-pyridine compounds non-obvious alternative |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t080620eu1.html
Date retrieved: 17 May 2021
18 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.EPC Articles
Offical Journal of the EPO
Case Law Book: II Conditions to be met by an Application
Case Law Book: IV Divisional Applications
Case Law Book: V Priority
XCLR V A 3.5.5 Review of an opposition division's discretionary decision (not) to admit a new ground for opposition